Identification of α-1L Adrenoceptor in Rabbit Ear Artery

The α-1L adrenoceptor (AR) was identified in rabbit ear artery by both functional and ligand binding studies. In functional studies using arterial rings, the contractile response to NS-49 [(R)-(-)-3′-(2-amino-1-hydroxyethyl)-4′-fluorometh-anesulfonanilide hydrochloride] (α-1A and α-1L AR-selective agonist) was competitively antagonized with low affinities by prazosin, RS-17053 [N-[2-(2-cyclopropylmethoxyphenoxy) ethyl]-5-chloro-α,α-dimethyl-1H-indole-3-ethamine hydrochloride], and 5-methylurapidil but with high affinities by tamsulosin and KMD-3213 [(-)-1-(3-hydroxypropyl)-5-[(2R)-2-({2-[(2,2,2-trifluoroethoxy)phenoxy]ethyl}amino)propyl]-2,3-dihydro-1H-indole-7-carboxamide]. In contrast, the response to noradrenaline (nonselective α-1 AR agonist) was inhibited noncompetitively by these antagonists (except 5-methylurapidil) with Schild slopes different from unity. These results suggest that the response to NS-49 was mediated predominantly via α-1L ARs, whereas the response to noradrenaline was produced through two distinct α-1 AR subtypes (presumably α-1B and α-1L ARs). In binding studies with intact segments of rabbit ear artery, [3H]KMD-3213 bound with high affinity (pKD = 9.7) to α-1 ARs, which were subdivided by prazosin, RS-17053, and 5-methylurapidil into two subtypes (α-1A and α-1L ARs). In contrast, [3H]prazosin binding sites in ear artery segments (pKD = 9.8) were identified as α-1A and α-1B ARs. In conventional binding studies using isolated rabbit ear artery microsomal membranes, [3H]KMD-3213 binding sites were identified as α-1A ARs with high affinities for prazosin, RS-17053, and 5-methylurapidil. Our study indicates that an α-1L AR having a unique pharmacological profile coexists with α-1A and α-1B ARs in rabbit ear artery and can be identified either functionally or by binding studies using intact tissues but not microsomal membrane preparations.

[1]  M. Kunitomo,et al.  Alpha‐1D adrenoceptors are involved in reserpine‐induced supersensitivity of rat tail artery , 2004, British journal of pharmacology.

[2]  Li Zhang,et al.  Alpha‐1 adrenoceptors: evaluation of receptor subtype‐binding kinetics in intact arterial tissues and comparison with membrane binding , 2004, British journal of pharmacology.

[3]  M. Michel,et al.  Classification of α1-adrenoceptor subtypes , 1995, Naunyn-Schmiedeberg's Archives of Pharmacology.

[4]  W. Schütz,et al.  Glomeruli and microvessels of the rabbit kidney contain both A1- and A2-adenosine receptors , 1987, Naunyn-Schmiedeberg's Archives of Pharmacology.

[5]  I. Muramatsu,et al.  Pharmacological profiles of a novel α1-adrenoceptor agonist, PNO-49 B, at α1-adrenoceptor subtypes , 2004, Naunyn-Schmiedeberg's Archives of Pharmacology.

[6]  Darrell R. Abernethy,et al.  International Union of Pharmacology: Approaches to the Nomenclature of Voltage-Gated Ion Channels , 2003, Pharmacological Reviews.

[7]  J. Guillebaud,et al.  Discrimination by SZL49 between contractions evoked by noradrenaline in longitudinal and circular muscle of human vas deferens , 2002, British journal of pharmacology.

[8]  Y. Akagi,et al.  Distribution of alpha‐1 adrenoceptor subtypes in RNA and protein in rabbit eyes , 2002, British journal of pharmacology.

[9]  J. Faber,et al.  Expression of α-Adrenoceptor Subtypes by Smooth Muscle Cells and Adventitial Fibroblasts in Rat Aorta and in Cell Culture , 2001 .

[10]  J. Faber,et al.  Expression of alpha-adrenoceptor subtypes by smooth muscle cells and adventitial fibroblasts in rat aorta and in cell culture. , 2001, The Journal of pharmacology and experimental therapeutics.

[11]  G. Michelotti,et al.  α1-Adrenergic receptor regulation: basic science and clinical implications , 2000 .

[12]  J. Pediani,et al.  Quantitative imaging in live human cells reveals intracellular alpha(1)-adrenoceptor ligand-binding sites. , 2000, The Journal of pharmacology and experimental therapeutics.

[13]  J. Hieble,et al.  Adrenoceptor subclassification: an approach to improved cardiovascular therapeutics. , 2000, Pharmaceutica acta Helvetiae.

[14]  J. Docherty,et al.  Investigation of the subtypes of α1‐adrenoceptor mediating contractions of rat vas deferens , 1999 .

[15]  Y. Akagi,et al.  Evaluation of α1‐adrenoceptors in the rabbit iris: pharmacological characterization and expression of mRNA , 1999, British journal of pharmacology.

[16]  T. Taniguchi,et al.  Pharmacological analysis of the novel, selective α1‐adrenoceptor antagonist, KMD‐3213, and its suitability as a tritiated radioligand , 1999, British journal of pharmacology.

[17]  Y. Watanabe,et al.  Binding and functional characterization of alpha1-adrenoceptor subtypes in the rat prostate. , 1999, European journal of pharmacology.

[18]  T. Taniguchi,et al.  Tamsulosin: alpha1-adrenoceptor subtype-selectivity and comparison with terazosin. , 1998, Japanese journal of pharmacology.

[19]  Y. Watanabe,et al.  Alpha1-adrenoceptor subtypes and two receptor systems in vascular tissues. , 1998, Life sciences.

[20]  J. Coleman,et al.  Tumour necrosis factor‐α expression and cell recruitment in Sephadex particle‐induced lung inflammation: effects of dexamethasone and cyclosporin A , 1997, British journal of pharmacology.

[21]  J. Hieble,et al.  Pharmacological characterization of the uroselective alpha-1 antagonist Rec 15/2739 (SB 216469): role of the alpha-1L adrenoceptor in tissue selectivity, part II. , 1997, The Journal of pharmacology and experimental therapeutics.

[22]  J. Blagg,et al.  Pharmacological options in the treatment of benign prostatic hyperplasia. , 1997, Journal of medicinal chemistry.

[23]  Ming Yang,et al.  Is α1D-adrenoreptor protein detactable in rat tissues? , 1997, Naunyn-Schmiedeberg's Archives of Pharmacology.

[24]  A. Ford,et al.  Pharmacological characterization of an α1A‐adrenoceptor mediating contractile responses to noradrenaline in isolated caudal artery of rat , 1997, British journal of pharmacology.

[25]  I. Dougall,et al.  Pharmacological classification of α1‐adrenoceptors mediating contractions of rabbit isolated ear artery: comparison with rat isolated thoracic aorta , 1997, British journal of pharmacology.

[26]  J. Hieble,et al.  Pharmacological characterization of the uroselective alpha-1 antagonist Rec 15/2739 (SB 216469): role of the alpha-1L adrenoceptor in tissue selectivity, part I. , 1997, The Journal of pharmacology and experimental therapeutics.

[27]  Astra Charnwood Pharmacological classification of a 1 -adrenoceptors mediating contractions of rabbit isolated ear artery: comparison with rat isolated thoracic aorta , 1997 .

[28]  M. Michel,et al.  Is alpha1D-adrenoceptor protein detectable in rat tissues? , 1997, Naunyn-Schmiedeberg's archives of pharmacology.

[29]  A. Hancock α1 Adrenoceptor subtypes: A synopsis of their pharmacology and molecular biology , 1996 .

[30]  T. Stamey,et al.  RS-17053 (N-[2-(2-cyclopropylmethoxyphenoxy)ethyl]-5-chloro-alpha, alpha-dimethyl-1H-indole-3-ethanamine hydrochloride), a selective alpha 1A-adrenoceptor antagonist, displays low affinity for functional alpha 1-adrenoceptors in human prostate: implications for adrenoceptor classification. , 1996, Molecular pharmacology.

[31]  I. Muramatsu,et al.  Identification of alpha 1-adrenoceptor subtypes in the rabbit prostate. , 1995, Journal of autonomic pharmacology.

[32]  R. Lefkowitz,et al.  International Union of Pharmacology. X. Recommendation for nomenclature of alpha 1-adrenoceptors: consensus update. , 1995, Pharmacological reviews.

[33]  A. Goetz,et al.  BMY 7378 is a selective antagonist of the D subtype of α1-adrenoceptors , 1995 .

[34]  A. Goetz,et al.  BMY 7378 is a selective antagonist of the D subtype of alpha 1-adrenoceptors. , 1995, European journal of pharmacology.

[35]  I. Muramatsu,et al.  Pharmacological profiles of a novel alpha 1-adrenoceptor agonist, PNO-49B, at alpha 1-adrenoceptor subtypes. , 1995, Naunyn-Schmiedeberg's Archives of Pharmacology.

[36]  H. Akino,et al.  Pharmacological characterization of alpha 1-adrenoceptor subtypes in the human prostate: functional and binding studies. , 1994, British journal of urology.

[37]  D. Bylund,et al.  Radioligand binding methods: practical guide and tips. , 1994, The American journal of physiology.

[38]  I. Muramatsu,et al.  Pharmacological characterization of two distinct α1‐adrenoceptor subtypes in rabbit thoracic aorta , 1993, British journal of pharmacology.

[39]  I. Muramatsu,et al.  Identification of α1‐adrenoceptor subtypes in the rat vas deferens: binding and functional studies , 1992 .

[40]  I. Muramatsu,et al.  Identification of alpha 1-adrenoceptor subtypes in the rat vas deferens: binding and functional studies. , 1992, British Journal of Pharmacology.

[41]  M. M. Bradford A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. , 1976, Analytical biochemistry.

[42]  R. Furchgott The Classification of Adrenoceptors (Adrenergic Receptors). An Evaluation from the Standpoint of Receptor Theory , 1972 .

[43]  H. Schild,et al.  SOME QUANTITATIVE USES OF DRUG ANTAGONISTS , 1997, British journal of pharmacology and chemotherapy.